AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023Business Wire • 02/01/23
Is the Options Market Predicting a Spike in AbCellera (ABCL) Stock?Zacks Investment Research • 01/24/23
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture PatentBusiness Wire • 01/20/23
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023Business Wire • 01/04/23
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare DiseasesBusiness Wire • 12/01/22
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022Business Wire • 11/10/22
AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical DevelopmentBusiness Wire • 11/02/22
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 11/01/22
Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to TradeZacks Investment Research • 10/21/22
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022Business Wire • 10/05/22
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the ClinicBusiness Wire • 09/21/22